Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: Implications for occupational safety

Pharmaceutical Journal

Volumn 268, Issue 7188, 2002, Pages 331-337

  Kiffmeyer, Thekla K ^a   Kube, Christine ^a   Opiolka, Siegfried ^a   Schmidt, Klaus Gerhard ^a   Schöppe, Günter ^a   Sessink, Paul J M ^a  

^a Institute of Energy and Environmental Technology IUTA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; ETOPOSIDE; FLUOROURACIL; FOSFOMYCIN;

AIR SAMPLING; ARTICLE; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG URINE LEVEL; EVAPORATION; GAS; HEALTH HAZARD; HOSPITAL PHARMACY; HUMAN; OCCUPATIONAL SAFETY; OPERATOR; PARAMEDICAL PERSONNEL; PARTICLE SIZE; RISK ASSESSMENT; TEMPERATURE DEPENDENCE; VAPOR PRESSURE;

EID: 0037045961     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs
2. Wischproben an Arbeitsplätzen mit Zytostatika-Exposition
3. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers applying a conceptual model to the results of three workplaces
4. Surface contamination with antineoplastic agents in six cancer treatment centres in Canada and the United States
5. Measurements of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments
6. Biological, cytogenetic and ambient monitoring of exposure to antineoplastic drugs
7. Application of high performance liquid chromatography tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide
8. Exposure of pharmacy technicians to antineoplastic agents; reevaluation after additional protective measures
9. Occupational exposure to antineoplastic agents and parameters for renal dysfunction
10. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs - Urinary excretion and cytogenetics studies
11. Determination of platinum in work-room air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy
12. Monitoring occupational exposure to cancer chemotherapy drugs
13. Controlling occupational exposure to hazardous drugs
14. Monitoring of occupational exposure to cytostatic anticancer agents
15. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide
16. Reproductie-toxische effecten bij ziekenhuispersoneel
17. Maternal ocupational risk factors for oral clefts. Occupational exposure and congenital malformation working group
18. Occupational exposure to antineoplastic agents: Self-reported miscarriages and still-births among nurses and pharmacists
19. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists
20. Laboratory work and pregnancy outcome
21. Menstrual cycles in nurses handling antineoplastic drugs
22. Ectopic pregnancy and occupational exposure to antineoplastic drugs
23. Adverse reproductive outcomes and occupational exposure among nurses
24. Occupational Exposure to cytotoxic drugs
25. Exposure to hazardous drugs: Time to reevaluate your program?
26. Exposure of hospital pharmacists and nurses to antineoplastic agents
27. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers
28. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route?
29. Detection of contamination with antineoplastic agents in a hospital pharmacy department
30. Exposure of hospital pharmacists and nurses to antineoplastic agents
31. Exposure of hospital workers to airborne antineoplastic agents
32. Determination of the vaporization of solutions of mutagenic agents at 23 and 37 degrees C using a desiccator technique
33. Aerosol technology
34. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry
35. Sample loss during measurement of airborne antineoplastic agents
36. Evaluation of the PhaSeal hazardous drug containment system